## VITROLIFE GROUP™

Press Release 20 January 2023 Gothenburg, Sweden

## Conference call Year-end report, 2022

Invitation to attend Vitrolife AB (publ) conference call regarding presentation of the Year-end report, 2022. The presentation will be held in English.

Time: Thursday 2 February, 2023 at 10.00 a.m. CET.

To attend the conference call, please use this link to register. After registration, you will be provided with telephone numbers, conference PIN, and personal PIN to access the conference.

https://event.loopup.com/SelfRegistration/registration.aspx?booking=E8jtNmAOot2RWoWD0PJuEDyn5H4sFi1T0nxRF8NSUto=&b=2389e96d-457b-46a8-bebb-fec356d5b031

Vitrolife participants: Thomas Axelsson, CEO Patrik Tolf, CFO

The press release for the year-end report will be released at 8.00 CET on the same day.

Before the conference call, presentation material will be available at the company web page, <a href="https://www.vitrolife.com/investors/Presentations/">https://www.vitrolife.com/investors/Presentations/</a>

A recorded version of the telephone conference will be available for seven days on number +44 (0) 20 3451 9993 (International), access code 6465516#.

Gothenburg, 20 January 2023 VITROLIFE AB (publ)

## Contact:

Patrik Tolf, CFO, phone +46 (0)31 766 90 21

Vitrolife Group is a global provider of medical devices and genetic services. Based on science and advanced research capabilities, we develop services and products for personalized genetic information and medical device products. We are supporting our customers by improving their clinical practice and the outcome of the patient's fertility treatment. Currently, we are approximately 1,100 people worldwide, headquartered in Gothenburg, Sweden.

Vitrolife Group's products and services are available in more than 110 countries, through our own presence in 30 countries and a network of distributors. We are a sustainable market leader and aim to be the preferred partner to the IVF-clinics by providing superior products and services with the vision to fulfil the dream of having a healthy baby. The Vitrolife share is listed on Nasdaq Stockholm.

Vitrolife AB (publ), Box 9080, SE-400 92 Gothenburg, Sweden. Corporate identity number 556354-3452.Tel: +46 31 721 80 00. Fax: +46 31 721 80 99. E-mail: info@vitrolife.com. Website: <a href="www.vitrolife.com">www.vitrolife.com</a>.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.